title: MRI safety update 2008: part 1, MRI contrast agents and nephrogenic systemic fibrosis.
abstract: OBJECTIVE
  This article is the first part of a two-part series on MRI safety. In this article, part 1, the topic of MRI contrast agents and nephrogenic systemic fibrosis (NSF) is addressed.
  
  
  CONCLUSIONS
  To prevent incidents and accidents associated with MRI, it is necessary to regularly revisit the safety topics that directly impact patient management especially with respect to the subjects that are "new" (e.g., MRI contrast agents and NSF), those that should be reassessed because of recent changes, topics that deserve emphasis because of controversy or confusion, and information that should be considered in light of new findings.
authors.affiliation: Keck School of Medicine, University of Southern California and Institute for Magnetic Resonance Safety, Education, and Research, 7511 McConnell Ave., Los Angeles, CA 90045, USA. frank.shellock@gte.net
authors.forename: Frank G
authors.initials: FG
authors.lastname: Shellock
authors.forename: Alberto
authors.initials: A
authors.lastname: Spinazzi
mesh_terms: D003287:Contrast Media / Q000009:adverse effects*; D005355:Fibrosis / Q000139:chemically induced / Q000175:diagnosis / Q000517:prevention & control; D005682:Gadolinium / Q000009:adverse effects*; D006801:Humans; D008279:Magnetic Resonance Imaging; D051437:Renal Insufficiency / Q000139:chemically induced* / Q000175:diagnosis / Q000517:prevention & control; D012871:Skin Diseases / Q000139:chemically induced* / Q000175:diagnosis / Q000517:prevention & control
chemical_list: D003287:Contrast Media; D005682:Gadolinium